Every Form 4 that Guardant Health, Inc. (GH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GH filings page.
Guardant Health director Tariq Musa reported routine equity compensation activity. On June 17, 2026, he exercised 4,203 Restricted Stock Units into the same number of common shares following full vesting tied to the 2026 Annual Meeting of Stockholders.
He also received a new grant of 2,711 Restricted Stock Units that will vest in full on the one-year anniversary of the grant date, June 17, 2026, or on the date of Guardant Health’s next annual meeting of stockholders, whichever is earlier. Following these transactions, Musa directly holds 12,999 shares of common stock and 2,711 Restricted Stock Units, with no shares sold.
Guardant Health director Myrtle S. Potter reported routine equity compensation activity. On June 17, 2026, she exercised 4,203 Restricted Stock Units, acquiring the same number of common shares and bringing her direct common stock holdings to 22,527 shares. A prior restricted stock unit award vested in full on the 2026 Annual Meeting date. She also received a new grant of 2,711 Restricted Stock Units, which will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.
Guardant Health director Roberto Mignone reported routine equity compensation activity. On June 17, 2026, he exercised restricted stock units covering 4,203 shares of Common Stock, bringing his direct Common Stock holdings to 8,954 shares after the transaction.
On the same date, he received a new grant of 2,711 Restricted Stock Units, each representing a right to receive one share of Common Stock. According to the footnotes, the RSU award that generated the 4,203 shares vested in full on the date of the 2026 Annual Meeting of Stockholders, while the new 2,711-unit award will vest in full on the earlier of the one-year anniversary of its June 17, 2026 grant date or the Company’s next annual meeting of stockholders.
Guardant Health director Steve E. Krognes reported equity compensation activity. On June 17, 2026, 4,203 Restricted Stock Units fully vested in connection with the company’s 2026 Annual Meeting of Stockholders and were converted into an equal number of shares of common stock.
Following this derivative exercise, Krognes held 14,425 shares of Guardant Health common stock directly. On the same date, he also received a new grant of 2,711 Restricted Stock Units, each representing a right to receive one share of common stock that will vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting.
Guardant Health, Inc. director Meghan V. Joyce reported the vesting and settlement of a restricted stock unit award into common stock. On June 17, 2026, coinciding with the company’s 2026 Annual Meeting of Stockholders, 4,203 restricted stock units converted into 4,203 shares of common stock at no exercise price. Following this compensation-related transaction, Joyce directly holds 15,386 shares of Guardant Health common stock, and no open-market purchases or sales were reported in this filing.
Guardant Health director Manuel Hidalgo Medina reported compensation-related equity activity on June 17, 2026. He exercised vested restricted stock units to acquire 4,435 shares of Common Stock at a conversion price of $0.00 per share and received a new grant of 2,711 restricted stock units. Following these transactions, one reported line shows direct ownership of 5,074 Common Stock shares and 2,711 restricted stock units, reflecting routine vesting and grants rather than open-market trading.
Guardant Health, Inc. director Vijaya Gadde reported routine equity compensation activity. On June 17, 2026, Gadde exercised restricted stock units covering 4,203 shares of Common Stock, increasing direct holdings to 28,517 shares. On the same date, Gadde also received a new award of 2,711 restricted stock units that will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.
Guardant Health director Ian T. Clark reported equity compensation activity tied to the 2026 Annual Meeting of Stockholders. A previously granted restricted stock unit (RSU) award vested in full on June 17, 2026 and was exercised into 5,092 shares of common stock, bringing indirect holdings in a family trust to 8,067 shares.
Clark also received a new grant of 2,711 RSUs on June 17, 2026. These RSUs convert into the same number of common shares and are scheduled to vest in full on the one-year anniversary of the grant date or on the date of Guardant Health’s next annual stockholder meeting, whichever occurs earlier. All reported transactions are acquisitions related to awards rather than open-market buying or selling.
Azar Alex M II reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health director Azar Alex M II received a grant of 2,711 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents the right to receive one share of common stock for no cash payment. The award vests in full on June 17, 2026, the one-year anniversary of the grant date, or on the date of Guardant Health’s next annual meeting of stockholders, whichever occurs earlier. Following this Form 4 transaction, Azar holds 2,711 RSUs directly.
Guardant Health Chief Information Officer Kumud Kalia reported routine stock-based compensation activity. On June 15, 2026, 638 restricted stock units converted into common shares, while 314 shares were withheld by the company to cover tax obligations. After these transactions, Kalia directly holds 41,414 common shares.
Guardant Health director Tariq Musa reported a small mix of stock transactions involving company shares. On June 15, 2026, a restricted stock unit (RSU) award converted into 250 shares of common stock at a stated price of $0.00 per share, reflecting vesting of previously granted equity compensation.
The same RSU award was originally granted on March 6, 2023 and vests over four years, with 25% vesting on March 15, 2024 and the remaining 75% vesting monthly over three years. On June 16, 2026, Musa executed an open-market sale of 116 shares of common stock at an average price of $130.19 per share. Following these transactions, he holds 8,796 shares of Guardant Health common stock directly.
Guardant Health Chief Legal Officer John G. Saia reported compensation-related stock activity on June 15, 2026. He exercised 1,020 restricted stock units into common shares, then had 535 of those shares withheld by the company at $129.82 per share to cover tax obligations, with no open-market sale. After these transactions, Saia directly holds 36,435 Guardant Health shares. The RSU award was granted on June 9, 2023 and vests over three years, with 33% vesting on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported routine equity compensation activity involving restricted stock units and common stock. On June 15, 2026, 1,402 restricted stock units were converted into an equal number of common shares as part of a previously granted award that vested over a three-year period.
To cover related tax obligations on this vesting, the company retained 594 common shares at a price of $129.82 per share, a non-market tax-withholding disposition rather than an open-market sale. Following these transactions, Freeman directly held 61,101 common shares of Guardant Health.
Guardant Health, Inc.’s Chief Financial Officer Michael Brian Bell reported routine equity compensation activity. On June 15, 2026, 2,039 Restricted Stock Units were converted into an equal number of shares of common stock, reflecting the vesting schedule of an award granted on June 9, 2023.
On the same date, 1,096 shares of common stock were withheld by the company to cover Mr. Bell’s tax withholding obligations tied to this vesting, with the shares valued at $129.82 each. After these transactions, Mr. Bell directly owned 48,452 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 3,418 shares of Common Stock on June 11, 2026 at an average price of $130.2386 per share. After this transaction, Kalia directly holds 41,090 shares, indicating he retains a substantial ongoing equity stake.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 5,000 shares of Common Stock. The shares were sold at a price of $130.406 per share. After this transaction, Kalia directly owns 44,508 shares, indicating a remaining substantial equity position.
Guardant Health, Inc. Co-Chief Executive Officer Helmy Eltoukhy reported a series of open-market sales of the company’s common stock on June 5, 2026. Through the Helmy A. Eltoukhy Revocable Trust, he sold a total of 100,000 shares in seven transactions at weighted average prices between about $124.95 and $132.55 per share. Following these sales, the trust continues to hold approximately 2,012,919 shares of Guardant Health common stock indirectly attributed to Eltoukhy.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell sold 2,000 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $128.6203 per share. Following this sale, he directly holds 47,509 shares of Guardant Health common stock.
The footnote explains that the sale occurred through multiple trades at prices ranging from $128.620 to $128.955 per share, and detailed trade-level information is available upon request.
Guardant Health director Steve E. Krognes sold shares in an open-market transaction. He sold 9,294 shares of Guardant Health common stock on June 4, 2026 at a weighted average price of $132.5072 per share, in multiple trades priced between $132.50 and $132.71. After this sale, he directly owns 10,222 Guardant Health shares.
Guardant Health, Inc. director Meghan V. Joyce reported option exercises and related share sales. On June 3, 2026, she exercised stock options to acquire a total of 10,000 shares of Guardant Health common stock at exercise prices of $38.005 and $38.420 per share.
On the same date, she executed open-market sales totaling 10,000 shares of common stock in multiple price tranches, at weighted average prices reported around the high $120s per share. Following these transactions, she directly holds 11,183 shares of Guardant Health common stock, and the exercised option positions have been fully converted into shares.
Guardant Health, Inc. director Steve E. Krognes reported a routine equity compensation event involving 154 shares. He exercised restricted stock units into 154 shares of Common Stock, classified as a derivative exercise rather than an open-market purchase or sale. Following this transaction, he holds 19,516 shares of Common Stock directly and 155 Restricted Stock Units.
The RSUs come from an award granted on August 9, 2022 that vested 25% of the shares on June 30, 2023, with the remaining 75% vesting in substantially equal monthly installments over three years. No shares were sold, gifted, or withheld for taxes in this filing.
Guardant Health, Inc. director Manuel Hidalgo Medina reported an open-market sale of 1,000 shares of Common Stock at an average price of $130.0601 per share. After this transaction on May 28, 2026, he directly holds 639 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported selling 10,000 shares of common stock in open-market transactions on May 27, 2026. The filing shows two sales: 6 shares at $126.08 per share and 9,994 shares at $125.083 per share.
A footnote explains that the reported price reflects a weighted average, with individual trades executed between $125.00 and $125.44 per share. The insider remains a shareholder after these sales, but the exact remaining position is not detailed in the provided data.
Guardant Health Chief Commercial Officer Chris Freeman exercised options to acquire 24,406 shares of common stock at $32.86 per share and on the same day completed an open-market sale of 24,406 shares at a weighted average price of $118.6741.
After these transactions, Freeman directly holds 60,034 shares of common stock and 701 remaining stock options with a $32.86 exercise price expiring on June 9, 2033. The exercised options come from a June 9, 2023 award that vests over three years.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported open-market sales of a total of 20,000 shares of common stock on May 20, 2026. The shares were sold in three separate transactions at weighted average prices around $105–$107 per share, each executed across multiple trades within narrow intraday price ranges. These transactions reduce his direct holdings but he continues to own Guardant Health stock after the sales.
Guardant Health, Inc. disclosed that the Talasaz and Eskandari 2017 Family Trust, an entity associated with Co-Chief Executive Officer AmirAli Talasaz, completed a series of open-market sales of the company’s common stock.
The filing shows that the trust sold a total of 210,000 shares of Guardant Health common stock on May 20, 2026, across multiple trades. Reported weighted-average sale prices ranged from about $100.95 to about $112.76 per share, with detailed trade-by-trade pricing available on request from the company or the SEC staff. Following these transactions, the trust held 1,886,504 shares of Guardant Health common stock indirectly attributable to Talasaz.
Guardant Health, Inc. director Ian T. Clark reported an indirect open-market sale of the company’s Common Stock. On May 20, 2026, a family trust associated with him sold 6,876 shares at a weighted average price of $106.9006 per share, in multiple trades between $106.85 and $106.99. Following the transaction, the trust held 2,975 shares of Guardant Health Common Stock indirectly on his behalf, and no derivative securities were reported in this filing.
Guardant Health director Manuel Hidalgo Medina reported an option exercise and related stock sales. On May 20, 2026, he exercised stock options to acquire 1,000 shares of common stock at an exercise price of $32.55 per share.
That same day, he completed open-market sales totaling 1,250 shares of common stock, including 250 shares at a weighted-average price of $107.073 per share and 1,000 shares at $107.0956 per share. After these transactions, he directly holds 1,639 shares of Guardant Health common stock and 13,029 stock options with a $32.55 exercise price that expire on July 17, 2034.
Guardant Health director Tariq Musa exercised equity awards and made a small stock sale. On May 15, 2026, 250 restricted stock units converted into common shares, and on May 18, 2026 he sold 116 common shares at $95.96 each, leaving 8,662 shares held directly.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares as part of his equity compensation. On May 17, 2026, 232 RSUs converted into 232 shares of common stock at a stated price of $0.00 per share, reflecting a vesting event rather than an open-market purchase.
Following the transaction, he held 1,889 shares of common stock directly and 6,033 restricted stock units. The RSU grant, awarded on July 17, 2024, vests over four years, with 25% vesting on July 17, 2025 and the remaining 75% vesting monthly over the subsequent three years.
Guardant Health Chief Technology Officer Darya Chudova had 8,705 Restricted Stock Units convert into Common Stock on May 15, 2026. To cover tax obligations, 4,679 shares of Common Stock were retained by Guardant Health, and she now directly holds 74,402 shares.
Guardant Health, Inc. Co-Chief Executive Officer and director AmirAli Talasaz reported an open-market sale of 50,000 shares of Common Stock on May 12, 2026. The shares were sold at a weighted average price of $100.32 per share in multiple trades.
After this transaction, 2,096,504 shares of Guardant Health Common Stock are reported as indirectly owned, held by the Talasaz and Eskandari 2017 Family Trust.
Guardant Health, Inc. director Steve E. Krognes exercised restricted stock units into common stock in a routine compensation-related transaction. On April 30, 2026, 154 common shares were acquired upon RSU vesting, bringing his direct common stock holdings to 19,362 shares.
The RSUs originated from an award granted on August 9, 2022, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over three years. After this vesting event, he holds 309 restricted stock units directly.
Guardant Health, Inc. director Roberto Mignone acquired 264 common shares through RSU vesting. On April 21, 2026, 264 Restricted Stock Units converted into 264 shares of common stock at a stated price of $0.00 per share, reflecting equity compensation rather than an open-market purchase or sale.
Following the transaction, Mignone directly holds 4,751 shares of common stock and 7,920 Restricted Stock Units. The RSUs come from an award granted on November 8, 2024 that vests over four years. According to the award terms, 25% of the RSUs vested on October 21, 2025, and the remaining 75% vests in equal monthly installments over the next three years.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares. On April 17, 2026, he acquired 232 shares of Guardant Health, Inc. common stock through a derivative exercise at a stated price of $0.00 per share.
Following the transaction, he directly holds 1,657 shares of common stock and 6,265 restricted stock units. The RSU award, granted on July 17, 2024, vests over four years, with 25% vesting on July 17, 2025 and the remaining 75% vesting monthly over the subsequent three years.
Guardant Health director Tariq Musa reported routine equity activity tied to a prior restricted stock unit (RSU) grant. On April 15, 2026, he exercised 250 Restricted Stock Units at $0.00, converting them into 250 shares of Common Stock. On April 16, 2026, he completed an open-market sale of 116 Common Stock shares at an average price of $84.83 per share.
Following these transactions, Musa directly holds 8,528 shares of Common Stock and 2,749 Restricted Stock Units. The RSU award, granted on March 6, 2023, vests over four years, with 25% vesting on March 15, 2024 and the remaining 75% vesting monthly over the next three years.
Guardant Health Chief Legal Officer John G. Saia reported routine equity compensation activity. On April 15, 2026, 7,569 restricted stock units converted into an equal number of Guardant Health common shares at no exercise price as part of a scheduled vesting.
Of these vested shares, 3,970 were retained by the company to satisfy Mr. Saia’s tax withholding obligations at a reference price of $84.86 per share, which is a tax-withholding disposition rather than an open-market sale. After these transactions, he directly owns 65,950 shares of Guardant Health common stock.
Guardant Health Chief People Officer sells shares in open market
Guardant Health, Inc.'s Chief People Officer, Terilyn J. Monroe, reported an open-market sale of 3,832 shares of Common Stock at $92.68 per share. After this transaction, she continues to hold 20,990 Guardant Health shares directly.
Guardant Health Chief Legal Officer John G. Saia reported routine equity compensation activity. On April 1, 2026, multiple tranches of restricted stock units vested and were exercised into a total of 11,461 shares of Common Stock at an exercise price of $0.00 per share.
To cover tax obligations related to the vesting, 6,013 Common Stock shares were retained by Guardant Health at a price of $91.15 per share, as disclosed in the footnotes. After these transactions, Saia directly held 62,351 Common Stock shares. The RSU awards were originally granted between November 2022 and March 2025 and vest over three- to four-year periods in quarterly installments.
Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported routine equity compensation activity tied to restricted stock units. On April 1, 2026, she acquired 8,019 shares of common stock upon vesting and related derivative exercises, then had 4,187 shares withheld by the company to cover tax obligations at $91.15 per share. After these transactions, she directly held 24,822 shares of common stock. The filing reflects compensation and tax withholding mechanics rather than open-market buying or selling.
Guardant Health Chief Information Officer Kumud Kalia reported routine equity compensation activity involving restricted stock units. On April 1, 2026, several restricted stock unit awards converted into a total of 10,044 shares of Common Stock, reflecting scheduled vesting from previously granted awards.
To cover related tax obligations, 5,092 Common Stock shares were withheld by Guardant Health at $91.15 per share, as described in the footnotes, and were not sold in the open market. After these transactions, Kalia directly holds 49,249 Common Stock shares, indicating an overall increase in his equity stake despite the tax withholding.
Guardant Health Chief Commercial Officer Chris Freeman reported routine equity compensation activity. On April 1, 2026, multiple installments of his restricted stock unit awards vested, resulting in the acquisition of 11,213 shares of Common Stock at an exercise price of $0.00 per share.
To cover tax obligations tied to this vesting, 4,750 shares were withheld by Guardant Health at a price of $91.15 per share, as noted in the footnotes. After these transactions, Freeman directly owned 60,034 shares of Guardant Health common stock. The RSU awards were originally granted between November 7, 2022 and March 12, 2025 and vest over three- to four-year periods in quarterly installments.
Guardant Health, Inc. Chief Medical Officer Craig Eagle reported routine equity compensation activity as several restricted stock unit awards vested on April 1, 2026. He exercised RSUs to acquire a total of 11,400 shares of common stock at an exercise price of $0.00 per share.
To satisfy related tax obligations, 5,779 shares of common stock were retained by the company at $91.15 per share, as described in the footnotes, rather than sold on the open market. Following these transactions, Eagle directly holds 72,001 shares of Guardant Health common stock.
Guardant Health Chief Technology Officer Darya Chudova reported routine equity compensation activity tied to vesting restricted stock units. On April 1, 2026, she acquired a total of 13,029 shares of Guardant Health common stock through the exercise and conversion of multiple restricted stock unit awards at a stated price of $0.00 per share.
To cover tax withholding obligations upon vesting, 7,005 shares were retained by the company at a price of $91.15 per share, as described in the footnotes. After these compensation-related transactions and tax withholding, Chudova directly holds 70,376 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell exercised restricted stock units into common shares and had shares withheld for taxes. On April 1, 2026, he converted multiple restricted stock unit awards into a total of 12,777 shares of common stock at a conversion price of $0.00 per share.
In a related tax-withholding transaction, 6,869 common shares were retained by the company at $91.15 per share to satisfy tax liabilities tied to the RSU vesting. After these transactions, Bell directly held 49,509 shares of Guardant Health common stock, reflecting routine equity compensation activity rather than an open-market trade.
Guardant Health, Inc. Co-Chief Executive Officer AmirAli Talasaz reported routine equity compensation activity involving restricted stock units (RSUs) and related common stock on March 31 and April 1, 2026. Several RSU awards vested and were converted into shares of common stock held largely through the Talasaz and Eskandari 2017 Family Trust. In connection with these vestings, a total of 18,515 shares of common stock were withheld by the company at prices of $92.37 and $91.15 per share to satisfy tax withholding obligations, rather than sold in open-market transactions. Following these transactions, the family trust held 2,146,504 shares of Guardant Health common stock, while Talasaz also retained a substantial number of unvested RSUs directly.
Guardant Health, Inc. co-Chief Executive Officer Helmy Eltoukhy reported routine equity compensation activity involving restricted stock units and related common stock. On March 31 and April 1, 2026, multiple restricted stock unit awards converted into an aggregate of tens of thousands of shares of common stock at a $0.00 exercise price.
To cover associated tax obligations upon these vesting events, a total of 18,515 shares of common stock were retained by the company at prices of $92.37 and $91.15 per share, characterized as tax-withholding dispositions rather than open-market sales. Following these transactions, a revocable trust associated with Eltoukhy held 2,112,919 shares of common stock, and he directly held 68,011 restricted stock units. The filing reflects compensation-related vesting and tax withholding, not discretionary market trading.
Guardant Health director Steve E. Krognes acquired 155 shares of Common Stock through the vesting and exercise of Restricted Stock Units. The transaction occurred on March 31, 2026 at an exercise price of $0.00 per share, reflecting a routine equity-compensation event rather than an open-market purchase.
The 155 Restricted Stock Units converted into 155 shares of Common Stock, increasing his direct Common Stock holdings to 19,208 shares following the transaction. He also continues to hold 463 Restricted Stock Units after this vesting. The underlying award was originally granted on August 9, 2022 and vests over four years, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over the subsequent three years.
Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units into an equal number of common shares at a price of $0.00 per share, reflecting a routine equity compensation event rather than an open-market trade.
After this derivative exercise, Mignone directly holds 4,487 shares of common stock and 8,184 restricted stock units. The vested RSUs come from an award granted on November 8, 2024 that vests 25% on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported an open-market sale of 348 shares of Guardant Health common stock on March 18, 2026, at an average price of $88.09 per share. After this transaction, he directly holds 8,394 shares of the company’s stock.